Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.

BACKGROUND: Advanced lung adenocarcinoma (LAC) is one of the most lethal malignancies worldwide. The aim of this study was to evaluate the global survival in a real-life cohort of patients with LAC harboring driver genetic alterations.
METHODS: A series of 1282 consecutive Sardinian LAC patients who underwent genetic testing from January 2011 through July 2016 was collected. Molecular tests were based on the clinical needs of each single case (EGFR-exon18/19/21, ALK, and, more recently, BRAF-exon15), and the availability of tissue (KRAS, MET, and presence of low-frequency EGFR-T790M mutated alleles at baseline).
RESULTS: The mean follow-up time of the patients was 46 months. EGFR, KRAS, and BRAF mutations were detected in 13.7%, 21.3%, and 3% of tested cases, respectively; ALK rearrangements and MET amplifications were found respectively in 4.7% and 2% of tested cases. As expected, cases with mutations in exons 18-21 of EGFR, sensitizing to anti-EGFR tyrosine kinase inhibitors (TKIs) agents, had a significantly longer survival in comparison to those without (p < 0.0001); conversely, KRAS mutations were associated with a significantly lower survival (p = 0.0058). Among LAC patients with additional tissue section available for next-generation sequencing (NGS)-based analysis, 26/193 (13.5%) patients found positive for even low-rate EGFR-T790M mutated alleles at baseline were associated with a highly significant lower survival in comparison to those without (8.7 vs. 47.4 months, p < 0.0001).
CONCLUSIONS: In addition to its predictive value for addressing targeted therapy approaches, the assessment of as more inclusive mutation analysis at baseline may provide clues about factors significantly impacting on global survival in advanced LAC patients.

Introduction

Lung cancer is currently one of the most incident and lethal malignancies; in accordance with data from the Global Cancer Observatory, in 2020 were estimated more than 2.2 million new cases and approximately 1.8 million deaths worldwide, and a continuously increasing trend for both the incidence and mortality rates is expected for the next 20 years [1]. The narrowness in the gap between incidence and mortality rates, witnesses the difficulties in the clinical management of patients with lung cancer, especially those diagnosed with advanced stage disease, and the persistence of high mortality rates in this subset of patients. It is currently estimated that less than 21% of lung cancer patients are alive after five years from diagnosis [2], and this depends on several factors, such as the silent clinical course of the disease that leads to a late diagnosis in most cases, advanced age, impaired lung function related with tobacco smoking, cardiovascular and other comorbidities, histological subtype of the disease, and others [3, 4]. Significant improvements in lung cancer survival have been obtained in the last decade with the introduction of two novel therapeutic approaches for patients affected by non-small cell lung cancer (NSCLC), a group of histological subtypes that includes approximately 85% of lung cancers: immunotherapy and gene targeted therapy.

Immunotherapy with immune check point inhibitors (ICIs) is currently available for all programmed death 1 (PD1)/programmed death ligand 1 (PDL1) positive NSCLC subtypes, while targeted therapies are limited to patients with lung adenocarcinoma harboring specific genetic alterations like EGFR, BRAF, and MET mutations, as well as ALK, ROS1, and RET rearrangements or NRTK1/2/3 gene fusions [5].

Tyrosine Kinase Inhibitors (TKIs) against mutations of the EGFR gene were the first to introduce survival benefits in patients with lung adenocarcinoma, opening a new era in this setting. Several clinical trials reported improved outcomes with first (i.e. gefitinib, erlotinib) and second (i.e. afatinib, dacomitinib) generation anti-EGFR TKIs, which however were time-limited because of the occurrence of resistance against these drugs, especially in patients with tumors harboring specific mutations, like the T790M mutation in exon 20 of the EGFR gene [6]. Currently a third generation anti-EGFR TKI, which overcomes most (but not all) the known resistances, is available (Osimertinib). Survival improvements have been mainly documented in clinical trials designed to investigate specific drugs or treatment combinations, but less is known from real-life studies investigating the prognostic impact in daily practice-selected patients. In addition, mutations in other genes like KRAS, BRAF or HER2 have been reported to be negative prognostic biomarkers in patients with lung adenocarcinoma, making the prognostic landscape more complex [7]. In the present study we investigated the global survival rates in a cohort of Sardinian patients with lung adenocarcinoma harboring driver genetic alterations in the EGFR, KRAS, BRAF, ALK and MET genes with the aim to examine their real-life impact on survival, and potential correlations with several demographic, life-habit and clinical factors.

Materials and methods

Patients

A series of consecutive Sardinian patients with a histologically proven diagnosis of locally advanced or metastatic lung adenocarcinoma who underwent genetic molecular testing were retrospectively enrolled from January 2011 through July 2016. The demographic and clinical data at the time of diagnosis were retrieved from medical records and pathology reports. Survival data were retrieved from the Cancer Registry of the Province of Sassari, which makes part of a wider web of tumor registries coordinated by the Italian Association for Tumor Registries (Associazione Italiana Registri Tumori, AIRTUM) [4]. Sardinian origin was ascertained through verification of the place of birth for all patients. All patients were informed about the aims of this study and, before the tissue sample was collected, provided written informed consent. The study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Committee for the Ethics of the Research and Bioethics of the National Research Council (CNR).

Molecular testing

For molecular testing, formalin-fixed paraffin-embedded (FFPE) tissue sections containing at least 80% of malignant cells from each tumor were obtained; in cases with lower neoplastic cell content, tissue sections underwent tumor macro-dissection using a single edge razor blade and a marked haematoxylin/eosin slide as a guide to remove unwanted tissue parts. All samples were processed at the Unit of Cancer Genetics of the National Research Council in Sassari (Italy), which performed routine molecular testing for all the Sardinian hospitals in the period of the study.

The molecular tests to perform were based on the clinical needs of each single case (mutations in exons 18, 19, and 21 of EGFR as firstly-required test; immediately afterwards, ALK rearrangements), and the availability of tissue to submit in further analysis of three genes not used in clinical practice for targeted therapies at the time of the study (mutations in all coding exons of KRAS and exon 15 of BRAF; MET rearrangements), but with active involvement in the pathogenesis of lung cancer. Overall, all patients who were screened for other driver mutations in addition to the EGFR ones underwent genetic analysis for all the remaining genes (KRAS, ALK, BRAF, MET) independently on the positive or negative result by the EGFR mutation testing.

In our series, EGFR-mutated patients were treated with first (Gefitinib, Erlotinib) or second generation (Afatinib) anti-EGFR TKI, whose duration of efficacy varied due to the acquisition of drug resistance, mainly based on occurrence of the T790M mutation in exon 20 of the EGFR gene (data not shown; Casula et al., manuscript in preparation).

For mutation analysis genomic DNA was isolated from tissue sections using a standard protocol, and DNA quality was assessed for each specimen, as previously described [8]. Briefly, paraffin was removed from formalin-fixed paraffin-embedded (FFPE) samples by treatment with Bio-Clear (Bio-Optica, Milan, Italy), and DNA was purified using the GeneRead DNA FFPE Kit, (Qiagen Inc., Valencia, CA, USA) following the manufacturer’s instructions. Yields of purified DNA were assessed by the Qubit dsDNA High-Sensitivity Assay Kit on the Qubit 2.0 Fluorometer (Life Thermofisher, Waltham, MA USA). Mutation analysis was conducted in the coding sequence of the following genes: EGFR (exons 18, 19, and 21), KRAS (exons 2, 3, and 4), and BRAF (exon 15). Quantitative measurements of mutations were based on pyrosequencing performed on a Pyro- Mark Q24 system (Qiagen Inc., USA) with a detection limit of 5–7%, following the manufacturer’s instructions [9]

Next-generation sequencing (NGS) was performed in 193 FFPE tissues using Ion S5-GeneStudio System and carried out by Ion Oncomine™ Focus Gene Assay which provides multiplexed target selection of 35 hotspot genes implicated in cancer research. Starting DNA and libraries were accurately quantified using a fluorescence-based quantification method, such as Qubit dsDNA HS. Result filtering, annotation, and data analysis workflow was performed by automated data transfer, from the Ion Torrent™ Server to the Ion Reporter Server for variant analysis. Coverage of > 300 reads and frequency of mutated alleles > 3% for gene amplicon, in order to get a total amount of at least 10 mutated alleles for each candidate amplicon, were usually adopted for mutation selection criteria at somatic level. To even verify the existence at baseline of tumor subclones carrying the EGFR-T790M variant, we arbitrarily decided to go below the above-mentioned threshold value in order to identify up to few mutated alleles—ranging from 3 (0.15%) to 28 (1.47%) EGFR-T790M variants with a coverage of about 1900 reads—using the Integrative Genomics Viewer (IGV) tool.

Fluorescence in situ hybridization (FISH) for MET, was carried out in interphase tumor cells using the specific CTB.13 N12 BAC probe (at the 7q31.2 locus) and the control centromere, labeled with Spectrum-Orange and Spectrum-Green (Vysis, Downer’s Grove, IL, USA), respectively. For ALK, we used the ALK Break Apart FISH Probe Kit (Vysis, USA), as the first methodology deployed widely according to the recommendations by the National Comprehensive Cancer Network/NCCN guidelines (Version 3.2011). For ALK, the presence of rearrangement was defined when ≥ 15% of cells were positive for FISH signals according to the indications provided for the ALK Break Apart FISH Probe Kit (Vysis, USA). Amplification of the MET gene was defined by the presence of at least one of the following: (a) candidate gene to control centromere ratio ≥ 2, according to the main criterion provided for assessing EGFR gene copy number in NSCLC; and/ or (b) presence of at least a tetrasomic signal (≥ 2.0 gene copies per control centromere) in more than 15% of cells.

Statistical analysis

Descriptive analysis for qualitative and quantitative variables was conducted using proportions and the mean ± standard deviation (SD) or median and interquartile range (IQR), respectively. Statistical differences between groups were compared using unpaired Student’s t-test, Mann–Whitney rank sum test, chi-square test or Fisher’s exact test as appropriate. Survival was investigated with Kaplan–Meier and Cox regression analyses. p ≤ 0.05 was considered statistically significant. Data were analyzed using MedCalc for MS Windows, version 15.4 64 bit (MedCalc Software, Ostend, Belgium).

Results

A total of 1440 patients with lung adenocarcinoma who underwent genetic test to establish the presence of targeted genetic alterations in the period under investigation were identified. Among them, 158 were excluded because of lack of detailed clinical and/or follow-up data. Finally, 1282 patients were enrolled. Table 1 summarizes the global demographic, clinical and mutational data of the patients enrolled.

Table 1

Demographic, clinical and mutational data of the patients included in the study

Total cases	1282
Age, median (IQR)	67 (60–73)
≤ 50, n (%)	100 (8.5)
> 50, n (%)	1182 (91.5)
Males, n (%)	848 (66)
Never smokers/ data available, n (%)	140/780 (17.9)
EGFR mutated/ analyzed (%)	176/1282 (13.7)
Exon 18, n (%)	11 (6.2)
Exon 19, n (%)	89 (50)
Exon 21, n (%)	78 (43.8)
KRAS mutated/analyzed (%)	201/944 (21.3)
Exon 2, n (%)	171 (85.1)
G12C	68 (39.8)
G12V	38 (22.2)
G12D	34 (19.9)
Other G12	21 (12.3)
G13D	10 (5.8)
Exon 3, n (%)	30 (14.9)
Q61H	15 (50)
Q61L	15 (50)
BRAF V600E mutated/analyzed (%)	28/944 (3)
ALK rearranged/analyzed (%)	41/880 (4.7)
MET amplified/analyzed (%)	14/692 (2)
Concomitant genetic alterations
EGFR + MET, n (%)	2 (0.3)
ALK + MET, n (%)	2 (0.3)
Follow-up time, mean (± SD), months	46.1 (± 27.4)
Survival, mean (± SD), months	19.9 (± 22.4)

EGFR mutation analysis was performed in all the 1282 cases, as it was the first to be introduced in clinical practice, while KRAS and BRAF testing was carried out in 944 cases with tissues available to analyze. As stated in Methods, all patients with available tumor tissue sample were screened for mutations in the entire series of additional candidate genes (KRAS, ALK, BRAF, MET) regardless of the positive or negative result of the EGFR mutation testing.

The study of ALK rearrangements started with the adoption of the test in clinical practice in 2012 and involved 880 patients, and since then also MET amplifications were searched in 692 cases with available samples. Eight hundred forty-eight (66%) of the patients enrolled were males, and the median age was 67 (IQR 60–73) years (Table 1). EGFR, KRAS, and BRAF mutations were detected in 176 (13.7%), 201 (21.3%), and 28 (3%) of tested cases, respectively. ALK rearrangements and MET amplifications were found respectively in 41 (4.7%) and 14 (2%) of tested cases. In two cases, EGFR simultaneous mutations in different exons were observed; only rare concomitant genetic alterations in different genes were observed (Table 1). The exons affected in each single mutated gene are summarized in Table 1. Further details on the specific subtypes of the genetic alterations found and their correlation with demographic, pathologic and smoking exposure data have been previously published in a larger series partially containing the current cases [10].

EGFR mutations were significantly more common in females and never smokers, as opposed to KRAS mutations which were significantly more frequent in males and ever smokers (Table 2). ALK rearrangements were more common in younger patients, with the difference being close to statistical significance. BRAF mutations were more common in males and smokers, but these differences did not reach statistical significance, while MET amplifications were significantly more frequent in females than in males (Table 2).

Table 2

Genetic alterations in accordance with the gender, smoking habit, and age of the patients tested

Males	Females	p	Never smokers	Ever smokers	p	Age ≤ 50	Age > 50	p
EGFR (n = 1282)
62/848 (7.3%)	114/434 (26.3)	< 0.0001	62/140 (44.3%)	114/641 (17.8%)	< 0.0001	18/100 (18%)	158/1182 (13.4%)	0.2537
KRAS (n = 944)
156/619 (25.2%)	45/325 (13.8%)	0.0001	14/133 (10.5%)	187/585 (32%)	< 0.0001	18/83 (21.7%)	183/861 (21.2%)	0.9613
BRAF (n = 944)
20/619 (3.2%)	8/325 (2.5%)	0.6453	2/133 (1.5%)	26/585 (4.4%)	0.1825	2/83 (2.4%)	26/861 (3%)	0.9794
ALK (n = 880)
26/592 (4.4%)	15/288 (5.2%)	0.7123	5/82 (6.1%)	36/398 (9%)	0.5140	6/57 (10.5%)	35/823 (4.2%)	0.0645
MET (n = 692)
5/471 (1%)	9/221 (4.1%)	0.0247	2/75 (2.7%)	12/345 (3.5%)	1.000	0/46 (0%)	14/646 (2.1%)	0.6883

Statistically significant values (p < 0.05) are evidenced in bold

The mean (± SD) follow-up time was 46.1 (27.4) months, and at the time of follow-up 994 (77.5%) patients were dead. The mean (± SD) survival in the global cohort was 19.9 (± 22.4) months. Considering only dead patients, the mean (± SD) overall survival was 15.8 (± 18.8) months; a significantly greater survival was observed in females in comparison to males (19 ± 22.1 vs 21.8 ± 23 months; p = 0.003) and never smokers in comparison to ever smokers (26.4 ± 23.7 vs 21.1 ± 22.5 months; p = 0.003). Among patients with EGFR mutations, the eleven patients with exon 18 mutations had a significantly lower survival in comparison with those with exon 19 and exon 21 mutations (8.8 ± 5.7 vs 24.9 ± 20.9 months; p = 0.0023); no such difference was detected between the latter or between patients with KRAS exon 2 and exon 3 mutations. Finally, 193 patients were tested for the EGFR-T790M mutation at baseline—before the beginning of the systemic treatment and independently on the result of the EGFR testing for TKI-sensitizing mutations—by a NGS assay; among them, 26 (13.5%) had a very limited amount (very few mutated alleles) of the EGFR-T790M variant and showed a significantly lower survival in comparison to those without (8.7 vs. 47.4 months, p < 0.0001).

Kaplan–Meier global survival estimates in accordance with the genetic alterations detected are depicted in Table 3.

Table 3

Survival in accordance with the genetic alterations found in the study. Values are expressed in mean (confidence interval 95%) months

Gene	Altered	Wild type	p
EGFR	36.5 (30.6–42.4)	28.4 (25.5–31.4)	< 0.0001
KRAS	24.4 (19.4–29.4)	32.5 (29.0–36.0)	0.0058
BRAF	32.5 (17.3–47.7)	30.7 (27.6–33.8)	0.7337
ALK	20.4 (12.8–27.9)	25.6 (22.2–28.9)	0.6493
MET	23.4 (10.2–36.6)	25.9 (22.2–29.5)	0.8454
EGFR
Males	33.9 (23.8–43.9)	26.4 (23.2–29.6)	0.0729
Females	36.7 (30.3–43.1)	31.9 (26.8–37.0)	0.0017
Smokers	33.1 (21.6–44.6)	26.4 (23.0–29.9)	0.1261
Never smokers	38.6 (30.3–46.8)	29.6 (20.6–38.6)	0.0275
KRAS
Males	23.4 (18.7–28.1)	29.1 (25.2–33.1)	0.3026
Females	24.2 (12.7–35.6)	36.5 (31.4–41.7)	0.0025
Smokers	24.0 (18.8–29.1)	27.8 (23.8–31.8)	0.4366
Never smokers	13.1 (6.7–19.4)	34.7 (27.8–41.5)	0.0055

Statistically significant value is evidenced in bold

Kaplan–Meier estimates showed that patients harboring EGFR mutations had a significantly longer survival in comparison to those without (p < 0.0001), as opposed to KRAS mutations, which was associated with a significantly lower survival (p = 0.0058). The Kaplan–Meyer survival curves of EGFR and KRAS mutated patients in comparison to those with wild-type tumors are depicted in Fig. 1, while Fig. 2 depicts the survival curves of patients with EGFR-T790M mutation in comparison to those without. EGFR mutations provide globally a significant survival advantage in females and never smokers as opposed to KRAS mutations, which were shown to be negative prognostic factors in the same subsets. No statistically significant differences in survival were found regarding the other genetic alterations investigated. In the Cox regression model summarized in Table 4, survival rates were evaluated after adjustment for the genetic alterations under investigation as well as for age, sex and smoking status; in this model EGFR mutations represented the only parameter, which impacted significantly on global survival.

Fig. 1

Kaplan–Meyer survival curves in patients with and without EGFR and KRAS mutations, respectively. Time is referred to follow-up months

Fig. 2

Kaplan–Meyer survival curves in patients with and without EGFR-T790M mutation. Time is referred to follow-up months

Table 4

Cox regression analysis including the main impacting factors and the genetic alterations under investigation

Factor	HR	95% CI	p
Age	0.9963	0.9846–1.0081	0.5352
Sex	1.1872	0.9033–1.5604	0.2184
Smoking status	1.0137	0.7085–1.4503	0.9407
EGFR	0.6254	0.4497–0.9561	0.0283
KRAS	0.9448	0.7419–1.2032	0.6453
BRAF	1.0292	0.5419–1.9546	0.9300
ALK	0.9213	0.5966–1.4227	0.7114
MET	0.8324	0.3904–1.7750	0.6349

Statistically significant value is evidenced in bold

Discussion

Our study evidenced that, among the driver genetic alterations evaluated, in patients with lung adenocarcinoma the main factor that positively impacts real-life survival is the presence of an EGFR mutation in exons 18, 19 or 21, especially when associated with the absence of the T790M mutation in exon 20, no smoking history and female sex. This, in addition to the fact that EGFR mutations are the most common druggable genetic alterations in lung adenocarcinomas (10–16% in Caucasians, up to 78% in Asians [7, 8, 10]), and the fact that our series does not include patients treated with the third generation TKI Osimertinib, confirm that anti-EGFR treatments represent the cornerstone of modern targeted therapies in this setting. Other studies showed better survival rates in females and never smokers [11, 12].

In addition, in our series patients with tumors with exon EGFR 18 mutations had a worse survival in comparison to those with exon 19 and 21 mutations, as previously described [13]. Of note, in our study, 26 patients (13.5% of those tested) had tumors harboring the T790M mutation in the same tissue sample used for EGFR mutation analysis; despite a very few amount of mutated alleles being detected by NGS assay, such a subset of patients presented a consistently worse prognosis in comparison with cases who did not had the T790M variant. The EGFR-T790M mutation alone accounts for up to 50% of resistances in TKIs, which affect the majority of patients within the first year of treatment, and is considered quite rare at diagnosis, being the main mechanism of acquired (or secondary) drug resistance [14-16]. In this sense, our data show that, even if such a mutation is present at sub-clonal level in about one tenth of cases at the time of diagnosis, it may somehow affect the tumor behavior by causing intrinsic (or primary) drug resistance and inducing poor prognosis. This underlines the need of searching this mutation right from the initial molecular testing in order to both detect primary resistance to first and second generation TKIs and better classify the LAC patients from the prognostic point of view. Therefore, the occurrence of EGFR-T790M needs to be assessed despite the fact that last generation TKI drugs provide survival advantages in patients with early detected and persistent EGFR-T790M mutation [17]. Nevertheless, recent studies reported that the presence of EGFR-T790M in combination with complex EGFR mutations is a negative prognostic factor in patients treated with Osimertinib [18], suggesting that the need for EGFR-T790M testing will not come to an end with third generation TKIs. It appears, therefore, essential to use the biopsy or surgery samples to perform wider genetic testing that includes numerous EGFR variants and other genetic alterations which impact prognosis and survival, dependently or independently with the development of resistance to TKIs, like ALK, KRAS, BRAF and MET alterations [6]. The advent of next generation sequencing (NGS) technologies allows wider genetic evaluations, but it is currently expensive and not immediately available, especially in centers with low case numbers. The last version (4-2021) of the National Comprehensive Cancer Network recommends, when feasible, testing be performed via a broad panel-based approach, and, if not available, provides recommendations for other testing methodologies [5].

KRAS mutations have been traditionally considered a negative prognostic factor in patients with lung adenocarcinoma [7], currently representing the biggest challenge for the modern precision oncology. This is because KRAS mutations are generally mutually exclusive with EGFR mutations, as in our series, despite the results of some studies, which found a certain degree of co-occurrence [19, 20]. As a result, KRAS mutations generally affect consistent percentages of Caucasian (21–33%, 21.3% in our series) and to a lesser extend Asian (2–15%) patients with lung adenocarcinoma [7, 10], representing therefore an attractive target for future treatments. Several studies and a recent meta-analysis evidenced that KRAS mutations have a worse prognosis and a reduced or absent response to EGFR TKIs [21]. However, other studies failed to show a per se negative prognostic impact of KRAS mutations in patients with lung adenocarcinomas [22]. In our study, KRAS mutations were associated with worst prognosis, especially when associated with tobacco smoking, but they were not confirmed as independent negative prognostic factor of survival in Cox regression analysis.

Similarly, BRAF mutations and MET amplifications did not show an independent prognostic role in our cohort. Nevertheless, these alterations are consistently rarer in comparison to KRAS and EGFR mutations, and probably larger numbers are necessary to better evaluate their prognostic role. In our series, patients with BRAF and MET genetic alterations did not receive any targeted treatment because no such treatment were available at the time of the study, despite BRAF was a well-established therapeutic target in other malignancies like melanoma [23]. Currently, Dabrafenib and Trametinib are recommended for patients with a BRAF-V600E mutation, which was the only mutation detected in all the 28 cases (3% of the total tested) in our series [5]; this will surely improve the prognostic role of BRAF mutations in lung cancer in the future. MET amplifications were detected only in 14 cases (2% of those tested) in our series, a percentage consistently low considering that MET amplifications have been extensively documented as a mechanism of acquired resistance in 5–22% EGFR-mutated NSCLC upon therapeutic pressure with EGFR-TKIs; in addition, only two of these amplifications co-occurred with EGFR mutations, and thus, in patients subsequently treated with TKIs [24]. This suggests that, as opposed to the EGFR-T790M mutation, MET amplification is rarely present at the time of diagnosis and thus, it is a rare cause of primary resistance to TKIs. Currently drugs for MET exon 14 skipping mutations, which occur in 1–10% of the cases [24, 25], have been approved for clinical use (Capmatinib, Crizotinib, Tepotinib) [5], making these mutations and the study of acquired gene amplifications essential for the clinical management of the patients.

As opposed to MET alterations, ALK fusions represent a well-established therapeutic target in lung cancer, as they are detected in 3–7% of NSCLCs and have been associated with an absence of smoking, younger age, and adenocarcinoma histology [26]. In our study, ALK rearrangements occurred in 4.7% of the cases tested with no particular predilection for age, sex or smoking habits; two of the rearrangements occurred in concomitance with MET amplification. Curiously, the median survival of ALK wild type patients was higher, although not statistically significant, in comparison to those with ALK rearrangement. Actually, we do not have a full knowledge of the clinical history of the systemic treatment among such a subset of patients; therefore, we are not sure whether this unexpected lower survival among cases with ALK rearrangement might be somehow due to a real-life ineffectiveness of the first generation ALK inhibitors. Further real-life studies are necessary to better evaluate this finding, and to extend it to more recent second line medications.

Our study has some limitations, mainly its retrospective design and molecular testing based primarily on clinical needs, which limited the availability of samples for testing all the driver genes in all the cases. In addition, no liquid biopsies have been included in the study, and thus data on acquired EGFR-T790M—related resistance are not available. On the other hand, our study includes globally a relevant number of daily-practice cases, offering a unique insight on the impact of the main driver genetic alterations on the prognosis of lung adenocarcinoma.

Conclusions

In conclusion, our results evidenced that the presence of EGFR mutations represent the most impacting, independent prognostic factor, regardless of the type of TKIs received and despite the occurrence of EGFR-T790M mutations in 13.5% of the cases tested—a percentage that appears higher than those reported in past studies though we classified positive cases using a very low threshold (at least 3 mutated alleles). Some of the genetic alterations (i.e. BRAF-V600 and KRAS-G12C) became recently druggable and this will certainly improve their role in improving overall survival. Data from future real-life studies based on a more comprehensive molecular classification at the time of diagnosis of the advanced disease are constantly necessary to better evaluate the real impact of specific genetic alterations and their corresponding targeted therapies in patients with lung cancer.